# Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.

> **NCT00389428** · PHASE1 · COMPLETED · sponsor: **Jazz Pharmaceuticals** · enrollment: 48 (actual)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** CPX-351 (Cytarabine:Daunorubicin) Liposome Injection

## Key facts

- **NCT ID:** NCT00389428
- **Lead sponsor:** Jazz Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-09
- **Primary completion:** 2008-12
- **Final completion:** 2009-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2012-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00389428

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00389428, "Multicenter Study of CPX-351(Cytarabine:Daunorubicin) Liposome Injection in Patients With Advanced Hematologic Cancer.". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT00389428. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*